NANG IMMANIVONG: Open Payments
NPI 1538567102 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$553 in 18 payments from 10 companies in 2025. Trend: 2023 $17 · 2024 $176 · 2025 $553
Food & beverage: $553
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $201 |
| ABIOMED | 2 | $145 |
| Amgen Inc. | 2 | $38 |
| Novo Nordisk Inc | 2 | $35 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Abbott Laboratories | 1 | $24 |
| Exact Sciences Corporation | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| ABBVIE INC. | 1 | $17 |
Products named: BREZTRI, REPATHA, Ozempic, AIRSUPRA, Kerendia, TRELEGY ELLIPTA, FREESTYLE LIBRE 3, The Cologuard Plus Collection Kit.
Industry payments across TX — which companies pay providers there.
